Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing

Biologic treatments are increasingly being used in the management of moderate to severe plaque psoriasis (PSO). Risankizumab (RZB) is a humanized monoclonal antibody that specifically blocks the p19 subunit of interleukin 23, which in turn regulates the activation, differentiation, and survival of T...

Descripción completa

Detalles Bibliográficos
Autores principales: Gracia-Cazaña, Tamara, Bernal-Masferrer, Laura, Morales-Callaghan, Ana María, Almenara-Blasco, Manuel, Gilaberte, Yolanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884449/
https://www.ncbi.nlm.nih.gov/pubmed/36721838
http://dx.doi.org/10.2147/CCID.S296544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884449/
https://www.ncbi.nlm.nih.gov/pubmed/36721838
http://dx.doi.org/10.2147/CCID.S296544

Ejemplares similares